Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk

Carcinogenesis

Volumn 33, Issue 9, 2012, Pages 1699-1706

  Lin, Jie ^a   Lu, Charles ^a   Stewart, David J ^a   Gu, Jian ^a   Huang, Maosheng ^a   Chang, David W ^a   Lippman, Scott M ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANKS1B GENE; APOPTOSIS; ARTICLE; BCL 2 GENE; CANCER RISK; CASP9 GENE; CONTROLLED STUDY; FEMALE; GENE CONTROL; GENE REPLICATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; APOPTOSIS; CARRIER PROTEINS; CASPASE 9; FEMALE; GENES, BCL-2; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; SIGNAL TRANSDUCTION;

EID: 84865568334     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs192     Document Type: Article

References (45)

1. Siegel, R. et al. (2012) Cancer statistics, 2010. CA Cancer J. Clin., 62, 10-29
2. Godtfredsen, N.S. et al. (2005) Effect of smoking reduction on lung cancer risk. JAMA, 294, 1505-1510.
3. Miller, Y.E. et al. (2003) Genetic susceptibility to lung cancer. Semin. Respir. Crit. Care Med., 24, 197-204.
4. Chen, B. et al. (2009) TRAIL-R1 polymorphisms and cancer susceptibility: an evidence-based meta-analysis. Eur. J. Cancer, 45, 2598-2605.
5. Thompson, C.B. (1995) Apoptosis is the pathogenesis and treatment of disease. Science, 267, 1456-1462.
6. Raff, M. (1998) Call suicide for beginners. Nature, 396, 119-122.
7. Li, H. et al. (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell, 94, 491-501.
8. Luo, X. et al. (1998) Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 94, 481-490.
9. Budihardjo, I. et al. (1999) Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol., 15, 269-290.
10. Ashkenazi, A. et al. (1999) Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol., 11, 255-260.
11. Kischkel, F.C. et al. (2001) Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J. Biol. Chem., 276, 9-46.
12. Park, J.Y. et al. (2006) Caspase 9 promoter polymorphisms and risk of primary lung cancer. Hum. Mol. Genet., 15, 1963-1971.
13. Son, J.W. et al. (2006) Polymorphisms in the caspase-8 gene and the risk of lung cancer. Cancer Genet. Cytogenet., 169, 121-127.
14. Ter-Minassian, M. et al. (2008) Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis, 29, 2147-2152.
15. Ulybina, Y.M. et al. (2009) Coding polymorphisms in Casp5, Casp8 and DR4 genes may play a role in predisposition to lung cancer. Cancer Lett., 278, 183-191.
16. Truong, T. et al. (2010) International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants. Carcinogenesis, 31, 625-633.
17. Teixeira, A.L. et al. (2011) Influence of TGFB1+869T>C functional polymorphism in non-small cell lung cancer (NSCLC) risk. J. Cancer Res. Clin. Oncol., 137, 435-439.
18. Lee, S.Y. et al. (2010) Polymorphisms in the caspase genes and the risk of lung cancer. J. Thorac. Oncol., 5, 1152-1158.
19. Hart, K. et al. (2011) A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer. Lung Cancer, 71, 123-129.
20. Spitz, M.R. et al. (2007) A risk model for prediction of lung cancer. J. Natl. Cancer Inst., 99, 715-726.
21. Amos, C.I. et al. (2008) Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet., 40, 616-622.
22. Li, M. et al. (2008) Evaluation of coverage variation of SNP chips for genome-wide association studies. Eur. J. Hum. Genet., 16, 635-643.
23. Evan, G. et al. (1998) A matter of life and cell death. Science, 281, 1317-1322.
24. Evan, G.I. et al. (2001) Proliferation, cell cycle and apoptosis in cancer. Nature, 411, 342-348.
25. Cotter, T.G. (2009) Apoptosis and cancer: the genesis of a research field. Nat. Rev. Cancer, 9, 501-507.
26. Hanahan, D. et al. (2000) The hallmarks of cancer. Cell, 100, 57-70.
27. Enjuanes, A. et al. (2008) Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res., 68, 10178-10186.
28. Kim, D.H. et al. (2009) Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia. Blood, 113, 2517-2525.
29. Morton, L.M. et al. (2009) Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiol. Biomarkers Prev., 18, 1259-1270.
30. Kelly, J.L. et al. (2010) Germline variation in apoptosis pathway genes and risk of non-Hodgkin lymphoma. Cancer Epidemiol. Biomarkers Prev., 19, 2847-2858.
31. Shivapurkar, N. et al. (2003) Apoptosis and lung cancer: a review. J. Cell Biochem., 88, 885-898.
32. Thomadaki, H. et al. (2006) BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit. Rev. Clin. Lab. Sci., 43, 1-67.
33. Ferron, P.E. et al. (1997) Combined and sequential expression of p53, Rb, Ras and Bcl-2 in bronchial preneoplastic lesions. Tumori, 83, 587-593.
34. Kalomenidis, I. et al. (2001) Combined expression of p53, Bcl-2, and p21WAF-1 proteins in lung cancer and premalignant lesions: association with clinical characteristics. Lung, 179, 265-278.
35. Hu, Y. et al. (2004) Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Clin. Cancer Res., 10, 7662-7670.
36. Martin, B. et al. (2003) Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br. J. Cancer, 89, 55-64.
37. Yaren, A. et al. (2006) Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis. Int. J. Clin. Pract., 60, 675-682.
38. Anagnostou, V.K. et al. (2010) High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer, 10, 186.
39. Allan, L.A. et al. (2009) Apoptosis and autophagy: regulation of caspase-9 by phosphorylation. FEBS J., 276, 6063-6673.
40. Soengas, M.S. et al. (1999) Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science, 284, 156-159.
41. Li, J. et al. (2006) Ankyrin repeat: a unique motif mediating protein-protein interactions. Biochemistry, 45, 15168-15178.
42. Schweizer, A. et al. (2007) Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. Structure, 15, 625-636.
43. Stadler, Z.K. et al. (2010) Genome-wide association studies of cancer. J. Clin. Oncol., 28, 4255-4267.
44. Gail, M. H. (2009) Value of adding single-nucleotide polymorphism genotypes to breast cancer risk model. J. Natl. Cancer Inst. 101, 959-963.
45. Wacholder, S. et al. (2010) Performance of common genetic variants in breast-cancer risk models. N. Engl. J. Med., 362, 986-993.